GeneGuide uses a novel, genetics-based approach aimed at identifying drug targets and compounds for the treatment of neuropsychiatric disorders.

GeneGuide targets cognitive and emotional domains that are characteristic for specific psychiatric diseases and well amenable to behavioral and genetic studies. Further, GeneGuide has developed a Genome-Based Drug Discovery (GBD2) technology allowing the identification of druggable targets based on unbiased genome-wide information related to cognitive, emotional, and brain-imaging data.

Database description.pdf

See paper on the genetics-based approach

Human genome–guided identification of memory-modulating drugs -> PNAS.pdf



Copyright © GeneGuide 2013-2017

Finding new treatments

through human genomics